 Neil Aggarwal
Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Outpatients | 4 | 2023 | 324 | 2.170 |
Why?
| | Oxygen | 6 | 2023 | 854 | 1.860 |
Why?
| | Acute Lung Injury | 11 | 2015 | 278 | 1.420 |
Why?
| | Macrophages, Alveolar | 5 | 2016 | 355 | 1.350 |
Why?
| | Pneumonia | 6 | 2018 | 579 | 1.020 |
Why?
| | T-Lymphocytes, Regulatory | 5 | 2015 | 357 | 0.950 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 6 | 2021 | 101 | 0.780 |
Why?
| | Positive-Pressure Respiration | 1 | 2018 | 70 | 0.620 |
Why?
| | Phagocytes | 1 | 2018 | 90 | 0.600 |
Why?
| | Oxygen Inhalation Therapy | 2 | 2014 | 124 | 0.560 |
Why?
| | Lung | 12 | 2018 | 3623 | 0.530 |
Why?
| | Leukocytes, Mononuclear | 1 | 2018 | 504 | 0.520 |
Why?
| | Smoke | 1 | 2016 | 137 | 0.510 |
Why?
| | Receptor, Adenosine A2A | 1 | 2013 | 21 | 0.450 |
Why?
| | Lipopolysaccharides | 9 | 2015 | 857 | 0.430 |
Why?
| | Immunity, Innate | 1 | 2018 | 744 | 0.410 |
Why?
| | Lung Injury | 2 | 2011 | 199 | 0.390 |
Why?
| | Hydroxychloroquine | 2 | 2020 | 59 | 0.370 |
Why?
| | Mice, Inbred C57BL | 15 | 2016 | 4887 | 0.360 |
Why?
| | Bacteria | 1 | 2016 | 751 | 0.360 |
Why?
| | Smoking | 2 | 2016 | 1478 | 0.350 |
Why?
| | Research Report | 2 | 2021 | 75 | 0.350 |
Why?
| | Macrophages | 1 | 2016 | 1311 | 0.340 |
Why?
| | Respiratory Insufficiency | 2 | 2023 | 289 | 0.340 |
Why?
| | Bronchoalveolar Lavage Fluid | 7 | 2013 | 605 | 0.320 |
Why?
| | Flow Cytometry | 3 | 2018 | 1072 | 0.320 |
Why?
| | Epithelial Cells | 4 | 2016 | 951 | 0.310 |
Why?
| | Wound Healing | 1 | 2009 | 270 | 0.300 |
Why?
| | Inflammation Mediators | 4 | 2016 | 497 | 0.300 |
Why?
| | Mice, Knockout | 8 | 2015 | 2664 | 0.290 |
Why?
| | Adult | 13 | 2023 | 31324 | 0.290 |
Why?
| | Mice | 14 | 2018 | 15446 | 0.290 |
Why?
| | Hospitalization | 4 | 2022 | 1778 | 0.290 |
Why?
| | Antiviral Agents | 2 | 2023 | 653 | 0.290 |
Why?
| | Immunophenotyping | 2 | 2018 | 276 | 0.280 |
Why?
| | Carotid Artery, Internal | 1 | 2006 | 34 | 0.270 |
Why?
| | Vaccination | 1 | 2014 | 1218 | 0.270 |
Why?
| | Carotid Artery Diseases | 1 | 2006 | 58 | 0.270 |
Why?
| | Phagocytosis | 2 | 2018 | 360 | 0.260 |
Why?
| | Humans | 35 | 2023 | 118251 | 0.250 |
Why?
| | Intracranial Aneurysm | 1 | 2006 | 99 | 0.250 |
Why?
| | Animals | 18 | 2018 | 33152 | 0.250 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 225 | 0.240 |
Why?
| | Lung Diseases | 2 | 2021 | 709 | 0.240 |
Why?
| | Biomedical Research | 2 | 2021 | 600 | 0.230 |
Why?
| | Gene Expression Profiling | 1 | 2009 | 1590 | 0.220 |
Why?
| | Public-Private Sector Partnerships | 2 | 2021 | 43 | 0.220 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2006 | 209 | 0.220 |
Why?
| | Ritonavir | 1 | 2023 | 70 | 0.220 |
Why?
| | Hypoxia | 3 | 2014 | 957 | 0.210 |
Why?
| | Pulmonary Circulation | 2 | 2021 | 423 | 0.210 |
Why?
| | Antibodies, Monoclonal | 3 | 2022 | 1279 | 0.210 |
Why?
| | Cytokines | 3 | 2016 | 1880 | 0.200 |
Why?
| | Cell Membrane Permeability | 2 | 2012 | 87 | 0.190 |
Why?
| | Male | 22 | 2023 | 57474 | 0.190 |
Why?
| | Education | 1 | 2021 | 104 | 0.190 |
Why?
| | Neutrophils | 4 | 2015 | 1142 | 0.180 |
Why?
| | Tidal Volume | 2 | 2018 | 74 | 0.180 |
Why?
| | Pulmonary Alveoli | 3 | 2015 | 375 | 0.180 |
Why?
| | Triglycerides | 2 | 2013 | 515 | 0.180 |
Why?
| | Antibodies | 1 | 2021 | 381 | 0.170 |
Why?
| | Financing, Government | 1 | 2019 | 39 | 0.170 |
Why?
| | Ventricular Function, Right | 1 | 2021 | 257 | 0.170 |
Why?
| | Serum Bactericidal Test | 1 | 2018 | 1 | 0.170 |
Why?
| | Rare Diseases | 1 | 2019 | 93 | 0.160 |
Why?
| | Pandemics | 3 | 2022 | 1338 | 0.160 |
Why?
| | Partial Pressure | 1 | 2018 | 29 | 0.160 |
Why?
| | Interinstitutional Relations | 1 | 2018 | 55 | 0.160 |
Why?
| | Blood Gas Analysis | 1 | 2018 | 69 | 0.160 |
Why?
| | Vascular Diseases | 1 | 2021 | 241 | 0.160 |
Why?
| | APACHE | 1 | 2018 | 61 | 0.160 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2018 | 69 | 0.160 |
Why?
| | Streptococcus | 1 | 2018 | 24 | 0.160 |
Why?
| | Endothelial Cells | 2 | 2016 | 717 | 0.160 |
Why?
| | Precision Medicine | 1 | 2021 | 354 | 0.150 |
Why?
| | Betacoronavirus | 1 | 2020 | 253 | 0.150 |
Why?
| | Disease Models, Animal | 5 | 2015 | 3676 | 0.150 |
Why?
| | Macrophage Activation | 1 | 2018 | 165 | 0.150 |
Why?
| | Cell Separation | 1 | 2018 | 293 | 0.140 |
Why?
| | Adoptive Transfer | 3 | 2015 | 203 | 0.140 |
Why?
| | Goals | 1 | 2018 | 164 | 0.140 |
Why?
| | Soot | 1 | 2016 | 22 | 0.140 |
Why?
| | Disease Susceptibility | 1 | 2018 | 330 | 0.140 |
Why?
| | Lung Transplantation | 1 | 2018 | 263 | 0.140 |
Why?
| | Critical Illness | 2 | 2018 | 661 | 0.140 |
Why?
| | Research | 1 | 2019 | 406 | 0.130 |
Why?
| | Leukocytosis | 1 | 2015 | 34 | 0.130 |
Why?
| | Chemokines | 2 | 2015 | 228 | 0.130 |
Why?
| | DNA Modification Methylases | 1 | 2015 | 14 | 0.130 |
Why?
| | Wasting Syndrome | 1 | 2015 | 11 | 0.130 |
Why?
| | Muscular Atrophy | 2 | 2015 | 80 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 347 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 338 | 0.130 |
Why?
| | Aged | 8 | 2022 | 19594 | 0.130 |
Why?
| | Tissue and Organ Procurement | 1 | 2018 | 247 | 0.130 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2012 | 165 | 0.130 |
Why?
| | Epithelium | 1 | 2016 | 303 | 0.130 |
Why?
| | Air Pollution, Indoor | 1 | 2016 | 115 | 0.130 |
Why?
| | Ubiquitin-Protein Ligases | 2 | 2015 | 147 | 0.120 |
Why?
| | Lipoprotein Lipase | 2 | 2013 | 62 | 0.120 |
Why?
| | Societies, Medical | 1 | 2018 | 701 | 0.120 |
Why?
| | Interleukin-10 | 2 | 2014 | 304 | 0.120 |
Why?
| | Particulate Matter | 1 | 2016 | 234 | 0.120 |
Why?
| | Critical Care | 1 | 2018 | 488 | 0.120 |
Why?
| | Azacitidine | 1 | 2015 | 119 | 0.120 |
Why?
| | Intensive Care Units | 1 | 2018 | 633 | 0.120 |
Why?
| | Muscle Proteins | 2 | 2015 | 218 | 0.120 |
Why?
| | Osteomyelitis | 1 | 2015 | 109 | 0.120 |
Why?
| | Lipoproteins | 2 | 2013 | 163 | 0.120 |
Why?
| | Bacteremia | 1 | 2015 | 161 | 0.120 |
Why?
| | Cells, Cultured | 4 | 2016 | 4044 | 0.120 |
Why?
| | Phenethylamines | 1 | 2013 | 19 | 0.110 |
Why?
| | United States | 8 | 2021 | 12488 | 0.110 |
Why?
| | Adenosine A2 Receptor Agonists | 1 | 2013 | 20 | 0.110 |
Why?
| | Colorado | 1 | 2023 | 4178 | 0.110 |
Why?
| | Forkhead Transcription Factors | 2 | 2015 | 181 | 0.110 |
Why?
| | Middle Aged | 8 | 2023 | 27510 | 0.110 |
Why?
| | Gene Knockout Techniques | 1 | 2013 | 104 | 0.110 |
Why?
| | Physical Conditioning, Animal | 1 | 2015 | 204 | 0.110 |
Why?
| | Aquaporin 5 | 1 | 2012 | 3 | 0.110 |
Why?
| | Air Pollutants | 1 | 2016 | 303 | 0.110 |
Why?
| | Sepsis | 1 | 2018 | 531 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 980 | 0.100 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 2 | 1 | 2011 | 1 | 0.100 |
Why?
| | Time Factors | 5 | 2016 | 6368 | 0.100 |
Why?
| | Adenosine | 1 | 2013 | 211 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 2015 | 817 | 0.100 |
Why?
| | Capillary Permeability | 1 | 2011 | 138 | 0.100 |
Why?
| | Retrospective Studies | 3 | 2023 | 12929 | 0.100 |
Why?
| | Exercise Therapy | 1 | 2015 | 355 | 0.100 |
Why?
| | Staphylococcal Infections | 1 | 2015 | 348 | 0.100 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2491 | 0.100 |
Why?
| | Aftercare | 2 | 2023 | 194 | 0.100 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 1130 | 0.100 |
Why?
| | Treatment Outcome | 5 | 2023 | 9319 | 0.090 |
Why?
| | Treatment Failure | 2 | 2022 | 340 | 0.090 |
Why?
| | Biomarkers | 2 | 2018 | 3567 | 0.090 |
Why?
| | HIV-1 | 1 | 2016 | 772 | 0.090 |
Why?
| | Genes, RAG-1 | 1 | 2009 | 12 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2659 | 0.090 |
Why?
| | Hypertension, Pulmonary | 1 | 2021 | 1784 | 0.090 |
Why?
| | Microtubules | 1 | 2012 | 240 | 0.090 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2009 | 25 | 0.090 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 70 | 0.090 |
Why?
| | Monocytes | 1 | 2012 | 511 | 0.090 |
Why?
| | Leukocyte Count | 1 | 2009 | 303 | 0.090 |
Why?
| | Cluster Analysis | 1 | 2009 | 479 | 0.080 |
Why?
| | Heart Failure | 1 | 2021 | 1967 | 0.080 |
Why?
| | Muscle, Skeletal | 2 | 2015 | 1515 | 0.080 |
Why?
| | Gene Regulatory Networks | 1 | 2009 | 238 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2011 | 685 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 764 | 0.080 |
Why?
| | Female | 9 | 2023 | 61261 | 0.080 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2011 | 232 | 0.080 |
Why?
| | T-Lymphocyte Subsets | 1 | 2009 | 393 | 0.070 |
Why?
| | Adipose Tissue | 1 | 2011 | 595 | 0.070 |
Why?
| | Patient Discharge | 2 | 2023 | 791 | 0.070 |
Why?
| | Homeodomain Proteins | 3 | 2015 | 469 | 0.060 |
Why?
| | Receptors, CXCR4 | 2 | 2016 | 80 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2006 | 2433 | 0.060 |
Why?
| | Gene Expression Regulation | 2 | 2012 | 2435 | 0.060 |
Why?
| | Tripartite Motif Proteins | 2 | 2015 | 31 | 0.060 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2009 | 979 | 0.060 |
Why?
| | Sensitivity and Specificity | 3 | 2018 | 1787 | 0.060 |
Why?
| | Nucleocapsid | 1 | 2022 | 17 | 0.050 |
Why?
| | Angiopoietins | 2 | 2013 | 14 | 0.050 |
Why?
| | Cell Line, Transformed | 2 | 2012 | 135 | 0.050 |
Why?
| | Epigenomics | 1 | 2022 | 106 | 0.050 |
Why?
| | HIV Infections | 1 | 2016 | 2454 | 0.050 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2002 | 43 | 0.050 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2021 | 110 | 0.050 |
Why?
| | Blotting, Western | 2 | 2016 | 1186 | 0.050 |
Why?
| | Phenotype | 2 | 2022 | 2937 | 0.050 |
Why?
| | Prospective Studies | 3 | 2023 | 6443 | 0.050 |
Why?
| | Random Allocation | 2 | 2012 | 344 | 0.050 |
Why?
| | User-Computer Interface | 1 | 2002 | 147 | 0.050 |
Why?
| | Review Literature as Topic | 1 | 2021 | 68 | 0.050 |
Why?
| | Macrophages, Peritoneal | 2 | 2012 | 96 | 0.050 |
Why?
| | Antimalarials | 1 | 2020 | 24 | 0.050 |
Why?
| | Drug Discovery | 1 | 2021 | 124 | 0.050 |
Why?
| | Cohort Studies | 2 | 2023 | 5078 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2022 | 341 | 0.050 |
Why?
| | Bronchoscopy | 1 | 2002 | 246 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2020 | 269 | 0.040 |
Why?
| | Airway Obstruction | 1 | 2002 | 167 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 538 | 0.040 |
Why?
| | Netherlands | 1 | 2018 | 62 | 0.040 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2021 | 232 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2022 | 536 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2022 | 964 | 0.040 |
Why?
| | Inflammation | 3 | 2015 | 2545 | 0.040 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2002 | 709 | 0.040 |
Why?
| | Computational Biology | 1 | 2021 | 541 | 0.040 |
Why?
| | ROC Curve | 1 | 2018 | 470 | 0.040 |
Why?
| | Risk Factors | 2 | 2022 | 8958 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2018 | 202 | 0.040 |
Why?
| | Bacterial Infections | 1 | 2018 | 226 | 0.040 |
Why?
| | Virus Diseases | 1 | 2018 | 197 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 1937 | 0.030 |
Why?
| | Graft Survival | 1 | 2018 | 497 | 0.030 |
Why?
| | Cooperative Behavior | 1 | 2018 | 401 | 0.030 |
Why?
| | Cell Count | 1 | 2016 | 315 | 0.030 |
Why?
| | Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2015 | 1 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2016 | 167 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 160 | 0.030 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2015 | 69 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2015 | 131 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2016 | 314 | 0.030 |
Why?
| | Cadherins | 1 | 2016 | 186 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2016 | 526 | 0.030 |
Why?
| | Sputum | 1 | 2016 | 291 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3169 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1379 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2016 | 295 | 0.030 |
Why?
| | Cell Lineage | 1 | 2016 | 316 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2015 | 198 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2015 | 141 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2016 | 299 | 0.030 |
Why?
| | Adipose Tissue, White | 1 | 2013 | 35 | 0.030 |
Why?
| | Benzylamines | 1 | 2012 | 39 | 0.030 |
Why?
| | Mice, Congenic | 1 | 2012 | 23 | 0.030 |
Why?
| | B7-2 Antigen | 1 | 2012 | 25 | 0.030 |
Why?
| | Heterocyclic Compounds | 1 | 2012 | 20 | 0.030 |
Why?
| | Cell Survival | 1 | 2016 | 1045 | 0.030 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 79 | 0.030 |
Why?
| | RING Finger Domains | 1 | 2012 | 2 | 0.030 |
Why?
| | Adipose Tissue, Brown | 1 | 2013 | 71 | 0.030 |
Why?
| | Quality of Life | 1 | 2023 | 2355 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 4521 | 0.030 |
Why?
| | Diet, Atherogenic | 1 | 2011 | 7 | 0.030 |
Why?
| | Chylomicrons | 1 | 2011 | 7 | 0.030 |
Why?
| | Ventilators, Mechanical | 1 | 2011 | 46 | 0.030 |
Why?
| | Lipoproteins, VLDL | 1 | 2011 | 20 | 0.030 |
Why?
| | Myofibroblasts | 1 | 2012 | 118 | 0.020 |
Why?
| | Cyclic GMP | 1 | 2011 | 107 | 0.020 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2011 | 49 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1482 | 0.020 |
Why?
| | Adenoviridae | 1 | 2011 | 191 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2011 | 240 | 0.020 |
Why?
| | Motor Activity | 1 | 2015 | 664 | 0.020 |
Why?
| | Obesity | 1 | 2022 | 2715 | 0.020 |
Why?
| | Trachea | 1 | 2011 | 225 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 1795 | 0.020 |
Why?
| | Down-Regulation | 1 | 2012 | 623 | 0.020 |
Why?
| | Muscle Strength | 1 | 2012 | 283 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3043 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2011 | 562 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 523 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1469 | 0.020 |
Why?
| | Fibroblasts | 1 | 2012 | 835 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2011 | 543 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1681 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2018 | 2230 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 6541 | 0.020 |
Why?
| | Cell Line | 1 | 2012 | 2693 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1514 | 0.020 |
Why?
| | Survival Rate | 1 | 2009 | 1716 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2012 | 2262 | 0.020 |
Why?
| | Proteins | 1 | 2011 | 935 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 1237 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2011 | 2657 | 0.010 |
Why?
| | Bronchography | 1 | 2002 | 10 | 0.010 |
Why?
| | Tracheal Stenosis | 1 | 2002 | 24 | 0.010 |
Why?
| | Blood Glucose | 1 | 2011 | 1936 | 0.010 |
Why?
| | Insulin | 1 | 2011 | 2157 | 0.010 |
Why?
| | Observer Variation | 1 | 2002 | 306 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 4688 | 0.010 |
Why?
|
|
Aggarwal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|